Kate Zielaskowski

Kate Zielaskowski

Auto-generated profile, based on publicly available information

Kate Zielaskowski

Clinical Research Finance, Memorial Sloan Kettering Cancer Center, New York, New York

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2017 in JMIR Research Protocols
Verified
Journal Article
Open access
JHJennifer Hay
Jennifer Hay
Marianne BerwickMarianne Berwick
Marianne Berwick
KZKate Zielaskowski
Kate Zielaskowski
KWKirsten Am White
Kirsten Am White
VRVivian M Rodríguez
Vivian M Rodríguez
DBDavid B Buller
David B Buller
Limited translational genomic research currently exists to guide the availability, comprehension, and appropriate use of personalized genomics in diverse general population subgroups. Melanoma skin cancers are preventable, curable, common in the general population, and disproportionately increasing in Hispanics. Variants in the melanocortin-1 receptor (MC1R) gene are present in approximately 50% of the population, are major factors in determining sun sensitivity, and confer a 2-to-3-fold increase in melanoma risk in the general population, even in populations with darker skin. Therefore, feedback regarding MC1R risk status may raise risk awareness and protective behavior in the general population. We are conducting a randomized controlled trial examining Internet presentation of the risks and benefits of personalized genomic testing for MC1R gene variants that are associated with increased melanoma risk. We will enroll a total of 885 participants (462 participants are currently enrolled), who will be randomized 6:1 to personalized genomic testing for melanoma risk versus waiting list control. Control participants will be offered testing after outcome assessments. Participants will be balanced across self-reported Hispanic versus non-Hispanic ethnicity (n=750 in personalized genomic testing for melanoma risk arm; n=135 in control arm), and will be recruited from a general population cohort in Albuquerque, New Mexico, which is subject to year-round sun exposure. Baseline surveys will be completed in-person with study staff and follow-up measures will be completed via telephone. Aim 1 of the trial will examine the personal utility of personalized genomic testing for melanoma risk in terms of short-term (3-month) sun protection and skin screening behaviors, family and physician communication, and melanoma threat and control beliefs (ie, putative mediators of behavior change). We will also examine potential unintended consequences of testing among those who receive average-risk personalized genomic testing for melanoma risk findings, and examine predictors of sun protection at 3 months as the outcome. These findings will be used to develop messages for groups that receive average-risk feedback. Aim 2 will compare rates of test consideration in Hispanics versus non-Hispanics, including consideration of testing pros and cons and registration of a decision to either accept or decline testing. Aim 3 will examine personalized genomic testing for melanoma risk feedback comprehension, recall, satisfaction, and cancer-related distress in those who undergo testing, and whether these outcomes differ by ethnicity (Hispanic vs non-Hispanic), or sociocultural or demographic factors. Final outcome data collection is anticipated to be complete by October 2017, at which point data analysis will commence. This study has important implications for personalized genomics in the context of melanoma risk, and may be broadly applicable as a model for delivery of personalized genomic feedback for other health conditions.

2 June 2018 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
JHJennifer Hay
Jennifer Hay
KZKate Zielaskowski
Kate Zielaskowski
KWKirsten Meyer White
Kirsten Meyer White
KKKimberly A. Kaphingst
Kimberly A. Kaphingst
ERErika Robers
Erika Robers
Marianne BerwickMarianne Berwick
Marianne Berwick
Melanoma is a common malignant neoplasm, and disproportionate increases in melanoma, particularly thicker tumors with poorer prognoses, have been documented in Hispanics in states with high levels of year-round sun exposure.1,2 In ethnically and racially diverse populations, melanoma results in greater morbidity and mortality due to the disease often being identified at later stages, and because of low physician and patient awareness that melanomas occur in these populations.1,3,4 Most individuals do not use sunscreen, wear protective clothing, or seek shade on a regular basis,5 and in the United States, approximately 35% of the population uses sunscreen consistently.6 This behavior extends to Hispanics of varying skin types,7 and Hispanics in the United States have high sunburn rates.8 Lower skin cancer awareness and perceived skin cancer risk have been identified as particular barriers to adequate and consistent sun protection in Hispanics.3,9-12 Personalized genomic testing for melanoma risk may promote risk awareness and risk reduction in the general population, including Hispanics.